TW202313973A - 使用藥物基因體學標記的組合物及方法 - Google Patents

使用藥物基因體學標記的組合物及方法 Download PDF

Info

Publication number
TW202313973A
TW202313973A TW111122709A TW111122709A TW202313973A TW 202313973 A TW202313973 A TW 202313973A TW 111122709 A TW111122709 A TW 111122709A TW 111122709 A TW111122709 A TW 111122709A TW 202313973 A TW202313973 A TW 202313973A
Authority
TW
Taiwan
Prior art keywords
snps
sequencing
treatment
snp
reagent
Prior art date
Application number
TW111122709A
Other languages
English (en)
Chinese (zh)
Inventor
文 羅
紅 孫
Original Assignee
美商索元生物醫藥有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商索元生物醫藥有限責任公司 filed Critical 美商索元生物醫藥有限責任公司
Publication of TW202313973A publication Critical patent/TW202313973A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
TW111122709A 2016-09-01 2017-08-31 使用藥物基因體學標記的組合物及方法 TW202313973A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662382734P 2016-09-01 2016-09-01
US62/382,734 2016-09-01
US201662414601P 2016-10-28 2016-10-28
US62/414,601 2016-10-28

Publications (1)

Publication Number Publication Date
TW202313973A true TW202313973A (zh) 2023-04-01

Family

ID=59923555

Family Applications (2)

Application Number Title Priority Date Filing Date
TW111122709A TW202313973A (zh) 2016-09-01 2017-08-31 使用藥物基因體學標記的組合物及方法
TW106129838A TWI771317B (zh) 2016-09-01 2017-08-31 使用藥物基因體學標記的組合物及方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW106129838A TWI771317B (zh) 2016-09-01 2017-08-31 使用藥物基因體學標記的組合物及方法

Country Status (15)

Country Link
US (2) US11421280B2 (enExample)
EP (1) EP3507384B1 (enExample)
JP (3) JP7197915B2 (enExample)
KR (1) KR20190046935A (enExample)
CN (1) CN109952383B (enExample)
AU (1) AU2017318669B2 (enExample)
BR (1) BR112019003951A2 (enExample)
CA (1) CA3035386A1 (enExample)
JO (1) JOP20190025A1 (enExample)
MX (1) MX2019002377A (enExample)
PH (1) PH12019500422A1 (enExample)
RU (1) RU2019109011A (enExample)
SG (2) SG10201912134TA (enExample)
TW (2) TW202313973A (enExample)
WO (1) WO2018045240A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190025A1 (ar) 2016-09-01 2019-02-19 Denovo Biopharma Llc طرق وتركيبة لتوقع نشاط إنزاستورين
CN110496223B (zh) * 2018-05-17 2021-09-10 复旦大学附属肿瘤医院 一种治疗非霍奇金氏淋巴瘤的药物组合物
CN112512527A (zh) * 2018-09-12 2021-03-16 杭州索元生物医药股份有限公司 恩扎妥林和btk抑制剂的组合及其用途
CN111549033B (zh) * 2020-06-11 2021-02-12 南京市江宁医院 慢病毒感染人表皮角质细胞株及其构建方法和应用
US11227690B1 (en) * 2020-09-14 2022-01-18 Opendna Ltd. Machine learning prediction of therapy response
EP4376022A4 (en) * 2021-07-23 2025-07-16 Univ Kaohsiung Medical CLINICAL THERAPEUTIC DRUG PREDICTION AND RECOMMENDATION SYSTEM AND METHOD FOR EVALUATING THE EFFICACY OF A SECOND-GENERATION HORMONAL DRUG IN THE TREATMENT OF PROSTATE CANCER
US20230131677A1 (en) * 2021-10-21 2023-04-27 Toyota Research Institute, Inc. Systems and methods for predicting the effect of an intervention via machine learning
CN118339312A (zh) * 2021-11-23 2024-07-12 索元生物医药(美国)有限公司 用于评估多核苷酸递送和癌疗法之功效的组合物和方法
US12474842B2 (en) * 2021-12-13 2025-11-18 Google Llc Optimizing data placement based on data temperature and lifetime prediction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2236702T3 (es) 1993-12-23 2005-07-16 Eli Lilly And Company Inhibidores de la proteina quinasa c.
WO2002014500A2 (en) 2000-08-16 2002-02-21 Chiron Corporation Human genes and gene expression products
US20040072217A1 (en) 2002-06-17 2004-04-15 Affymetrix, Inc. Methods of analysis of linkage disequilibrium
CA2393720C (en) 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
WO2007145992A2 (en) 2006-06-05 2007-12-21 Perlegen Sciences, Inc. Genetic basis of treatment response in depression patients
WO2012106267A1 (en) 2011-01-31 2012-08-09 Wen Luo Method for discovering pharmacogenomic biomarkers
CN103649386B (zh) * 2011-06-08 2015-12-23 索元生物医药（杭州）有限公司 预测类视黄醇x受体调节剂活性的方法和组合物
JOP20190025A1 (ar) 2016-09-01 2019-02-19 Denovo Biopharma Llc طرق وتركيبة لتوقع نشاط إنزاستورين

Also Published As

Publication number Publication date
PH12019500422A1 (en) 2019-05-27
US20190233902A1 (en) 2019-08-01
US11421280B2 (en) 2022-08-23
AU2017318669A1 (en) 2019-03-07
AU2017318669B2 (en) 2023-04-20
JP2022173308A (ja) 2022-11-18
RU2019109011A (ru) 2020-10-05
CA3035386A1 (en) 2018-03-08
CN109952383A (zh) 2019-06-28
SG11201901762WA (en) 2019-03-28
EP3507384A1 (en) 2019-07-10
KR20190046935A (ko) 2019-05-07
JP7197915B2 (ja) 2022-12-28
TW201812125A (zh) 2018-04-01
CN109952383B (zh) 2024-01-05
JOP20190025A1 (ar) 2019-02-19
BR112019003951A2 (pt) 2019-06-25
MX2019002377A (es) 2019-09-05
US20230074781A1 (en) 2023-03-09
TWI771317B (zh) 2022-07-21
RU2019109011A3 (enExample) 2021-01-22
EP3507384B1 (en) 2023-08-30
WO2018045240A1 (en) 2018-03-08
JP2020188816A (ja) 2020-11-26
JP2019528705A (ja) 2019-10-17
SG10201912134TA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
US20230074781A1 (en) Methods and composition for the prediction of the activity of enzastaurin
US20210108266A1 (en) Method for discovering pharmacogenomic biomarkers
CN103649386B (zh) 预测类视黄醇x受体调节剂活性的方法和组合物
US10954563B2 (en) Method for predicting the onset of extrapyramidal symptoms (EPS) induced by an antipsychotic-based treatment
US20230193388A1 (en) Compositions and methods for assessing the efficacy of inhibitors of neurotranmitter transporters
US20240417801A1 (en) Compositions and methods for assessing the efficacy of polynucleotide delivery and cancer therapy
HK40011257B (en) Methods and composition for the prediction of the activity of enzastaurin
HK40011257A (en) Methods and composition for the prediction of the activity of enzastaurin
HK40083504A (en) Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters
HK1196399B (en) Method for discovering pharmacogenomic biomarkers
HK1196399A (en) Method for discovering pharmacogenomic biomarkers